About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Subscribe To Our Newsletter & Stay Updated
